Replies to post #2514 on Enanta Pharmaceuticals Inc (ENTA)

[Jake2234]

Indeed, yes.

But the primary is safety!

[vinmantoo]

Is the EDP-235 phase 2 designed to show if 235 stops the spread of Covid in 2-4 days after patients start?

Randy, I doubt it. Below is the link from the ENTA web site. Here is the relevant passage about the phase 2 SPRINT trial of EDP-235.

Patients will receive EDP-235 orally at a dose of 200mg or 400mg or placebo once daily for five days. The primary objective of the study is to evaluate the safety and tolerability of EDP-235. Secondary objectives include the evaluation of virologic endpoints, clinical symptoms and outcomes, and pharmacokinetics

.

The secondary outcomes deal with viral levels and it doesn't mention assessing spread in a household.

https://www.enanta.com/patients/patients-overview/

I also did some digging and found the Paxlovid trial which failed to significantly slow/stop spread in households. There were 3,000 people in that trial, which is far more than in the EDP-235 SPRINT trial. That indicates SPRINT isn't powered to be able to assess effect on household spread.

https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-covid-treatment-paxlovid-fails-prevent-infection-household-members-2022-04-29/#:~:text=April%2029%20(Reuters)%20%2D%20Pfizer,someone%20infected%20with%20the%20virus.